Breaking News

Samsung Biologics Accelerates Timeline of New Fifth Plant

Key features of Plant 5 include seamless process integration and optimization, advanced automation, and sustainable systems.

Samsung Biologics, a contract development and manufacturing organization (CDMO), reported that it plans to have its new fifth plant operational by April 2025. On June 1, the company fully completed its latest and the world’s largest biomanufacturing plant, Plant 4. As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest construction timeline, made possible by the company’s standardized...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters